Successful treatment of pyoderma gangrenosum with Janus kinase 1/2 inhibition

Keyphrases

• Pyoderma Gangrenosum 100%
• Janus Kinase 1 (JAK1) 100%
• Successful Treatment 100%
• Comorbidity 40%
• Intravenous Immunoglobulin (IVIg) 40%
• Plethora 20%
• Treatment Strategy 20%
• Disease Course 20%
• Small Molecules 20%
• Elderly Patients 20%
• Lower Leg 20%
• Promising Treatment 20%
• Hard to Treat 20%
• Methotrexate 20%
• Older Women 20%
• Complete Remission 20%
• Therapy Options 20%
• Ulcer 20%
• Leg Ulceration 20%
• Rheumatoid Arthritis 20%
• Mycophenolate Mofetil 20%
• Lymphopenia 20%
• Baricitinib 20%
• Systemic Glucocorticoids 20%
• Autoinflammatory Diseases 20%
• Infliximab 20%
• Steroid-sparing 20%
• 85-year-old 20%

Immunology and Microbiology

• Intravenous Immunoglobulin 100%
• Comorbidity 100%
• Inflammatory Arthritis 50%
• Autoinflammatory Syndromes 50%
• Immunosuppressant 50%
• Methotrexate 50%
• Biological Product 50%
• Infliximab 50%
• Lower Leg 50%
• Lymphocytopenia 50%
• Mycophenolate Mofetil 50%
• Glucocorticoid 50%

Medicine and Dentistry

• Pyoderma gangrenosum 100%
• Janus Kinase 1 100%
• Comorbidity 40%
• Venous Ulcer 20%
• Side Effect 20%
• Disease Course 20%
• Elderly Patient 20%
• Rheumatoid Arthritis 20%
• Leg Ulcer 20%
• Biological Product 20%
• Glucocorticoid 20%
• Mycophenolate Mofetil 20%
• Lower Leg 20%
• Lymphocytopenia 20%
• Baricitinib 20%
• Autoinflammatory Disease 20%
• Ulcer 20%
• Immunosuppressant 20%
• Methotrexate 20%
• Infliximab 20%
• Inflammatory Arthritis 20%